Please login to the form below

Not currently logged in
Email:
Password:

Actavis mounts patent challenge on Velcade in US

Plans to launch own version of Takeda’s cancer drug

Takeda, Velcade

Generic drugmaker Actavis has filed a legal challenge against Takeda subsidiary Millennium Pharmaceuticals seeking to overturn its US patent protection on multiple myeloma and mantle cell lymphoma treatment Velcade.

Actavis' new parent company Watson Pharmaceuticals said the company had filed for approval of a generic product based on bortezomib, the active ingredient in Velcade, and had promptly been sued by Millennium for patent infringement.

Under US law, the lawsuit introduces an immediate 30-month stay on FDA approval of the generic unless Actavis can overturn patents protecting Velcade.

Millennium's defence of Velcade rests on two US patents (6,713,446 and 6,958,319) which were filed in 2005 and are both due to expire on January 5, 2022, according to court documents filed by the company.

Velcade is Millennium's biggest-selling product and had sales of around $740m in the 12 months ending October 31, 2012, according to IMS Health data.

The drug acts as a proteasome inhibitor and was first approved in the US in 2003 as an intravenous therapy and is now also available in a subcutaneous formulation.

Outside the US it is marketed by Johnson & Johnson, which said in November it recorded almost $1bn in sales for the product in the first nine months of 2012, a 16 per cent increase driven by approvals of the subcutaneous formulation in the EU and Canada.

2nd January 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

BrAInPME.png
The future of medical content: The personal touch
The purpose of delivering personalised content to HCPs is not just about customer experience, it's about improving healthcare. Our Commercial Director, Tib Catania discusses what ‘deep learning’ means for the...
Rise of the patient expert - an interview with Michael Seres
Founded by Michael Seres in 2011, 11 Health is a connected medical device company currently working to change the lives of patients using stoma bags. Content Marketing Manager Liz Inskip...
Making sense of Nutraceuticals in China
Published in eyeforpharma February 2017 by Marc Yates...

Infographics